top of page

54 million Americans suffer from obstructive sleep apnea (OSA) every night.

2x

Risk of heart attack, stroke and diabetes.

50%

Patients fail CPAP therapy.

$150 Billion

Spent yearly on untreated OSA in the US

Current treatment methods are invasive and ineffective

Introducing Somnair

The first non-invasive treatment for
OSA sufferers

Somnair is a novel non-invasive neurostimuation device that opens the airway using a proprietary therapy delivery system. 

Patent Pending

nerve.png

Neurostimulation Therapy

Picture3.png

Non-Invasive

Picture2.png

Deployed at Home

Subscribe to our newsletter • Don’t miss out!

Thanks for subscribing!

Get in Touch

The Somnair device is currently in the pre-clinical development stage and is not yet commercially available. It is on the pathway to clinical studies, and any information provided is subject to change as research progresses.

bottom of page